Literature DB >> 19817550

DNA methylation and cancer diagnosis: new methods and applications.

Pierre Dehan1, Gaelle Kustermans, Samuel Guenin, Julie Horion, Jacques Boniver, Philippe Delvenne.   

Abstract

Methylation of cytosines in cytosine-guanine (CpG) dinucleotides is one of the most important epigenetic alterations in animals. The presence of methylcytosine in the promoter of specific genes has profound consequences on local chromatin structure and on the regulation of gene expression. Changes in DNA methylation play a central role in carcinogenesis. Hypermethylation and consecutive transcriptional silencing of tumor-suppressor genes has been documented in numerous cancers. The identification of target genes silenced by this modification has a great impact on diagnosis, classification, definition of risk groups and prognosis of cancer patients. Here we outline genome-wide techniques aiming at the identification of relevant methylated promoters. Methods and applications allowing clinicians to monitor the methylation of target genes will be also reviewed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19817550     DOI: 10.1586/erm.09.53

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  29 in total

1.  Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis.

Authors:  Liangjing Wang; Shujie Chen; Meng Xue; Jing Zhong; Xian Wang; Lihong Gan; Emily K Y Lam; Xin Liu; Jianbin Zhang; Tianhua Zhou; Jun Yu; Hongchuan Jin; Jianmin Si
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.

Authors:  Ying-Li Lin; Xiao-Qiang Liu; Wen-Ping Li; Guang Sun; Chun-Ting Zhang
Journal:  Int Urol Nephrol       Date:  2011-04-24       Impact factor: 2.370

3.  CTHRC1 is upregulated by promoter demethylation and transforming growth factor-β1 and may be associated with metastasis in human gastric cancer.

Authors:  Ping Wang; Ying-Chao Wang; Xiao-Yu Chen; Zhi-Yong Shen; Hui Cao; Yan-Jie Zhang; Jian Yu; Jing-De Zhu; You-Yong Lu; Jing-Yuan Fang
Journal:  Cancer Sci       Date:  2012-05-17       Impact factor: 6.716

Review 4.  Epigenetics and cancer.

Authors:  Rajnee Kanwal; Sanjay Gupta
Journal:  J Appl Physiol (1985)       Date:  2010-03-04

Review 5.  Cancer chemoprevention by dietary polyphenols: promising role for epigenetics.

Authors:  Alexander Link; Francesc Balaguer; Ajay Goel
Journal:  Biochem Pharmacol       Date:  2010-06-26       Impact factor: 5.858

6.  5-aza-2'-deoxycytidine, a DNA methylation inhibitor, attenuates hyperoxia-induced lung fibrosis via re-expression of P16 in neonatal rats.

Authors:  Shi-Meng Zhao; Hong-Min Wu; Mei-Ling Cao; Dan Han
Journal:  Pediatr Res       Date:  2017-12-20       Impact factor: 3.756

Review 7.  Epigenetic modifications in cancer.

Authors:  R Kanwal; S Gupta
Journal:  Clin Genet       Date:  2011-12-08       Impact factor: 4.438

Review 8.  DNA methylation as a universal biomarker.

Authors:  Victor V Levenson
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

Review 9.  Epigenetic modifications by dietary phytochemicals: implications for personalized nutrition.

Authors:  Sharmila Shankar; Dhruv Kumar; Rakesh K Srivastava
Journal:  Pharmacol Ther       Date:  2012-11-16       Impact factor: 12.310

10.  Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.

Authors:  Fatma Trifa; Sondes Karray-Chouayekh; Zeineb Ben Jmaa; Emna Jmal; Abdelmajid Khabir; Tahia Sellami-Boudawara; Mounir Frikha; Jamel Daoud; Raja Mokdad-Gargouri
Journal:  Med Oncol       Date:  2013-01-13       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.